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Abstract
Objective: To determine whether the presence of chronic obstructive lung disease (COPD) and reduction of lung function
parameters were predictors of mortality in a cohort.
Materials/Patients and Methods: Population based cohorts were followed in Montevideo, Santiago and Sao Paulo during 5,
6 and 9 years, respectively. Outcomes included all-cause, cardiovascular, respiratory and cancer mortality; exposures were
COPD, forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). Cox regression was used for analyses.
Sensitivity, specificity, positive and negative predictive values, receiver operator characteristics curves and Youden’s index
were calculated.
Results: Main causes of death were cardiovascular, respiratory and cancer. Baseline COPD was associated with overall
mortality (HR= 1.43 for FEV1/FVC,LLN; 2.01 for GOLD 2-4; 1.46 for GOLD 1-4; 1.50 for FEV1/FEV6 ,LLN). For cardiovascular
mortality, significant associations were found with GOLD 2-4 (HR= 2.68) and with GOLD 1-4 (HR= 1.78) for both genders
together (not among women). Low FEV1 was risk for overall and respiratory mortality (both genders combined). FVC was
not associated with overall mortality. For most COPD criteria sensitivity was low and specificity high. The area under the
curve for FEV1 was greater than for FVC for overall and cardiovascular mortality.
Answer to the Question: COPD and low FEV1 are important predictors for overall and cardiovascular mortality in Latin
America.
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Introduction
Over the next 20 years, a dramatic rise in chronic obstructive
lung disease-related (COPD) morbi-mortality is expected world-
wide [1]. In 2005, results from the first population-based multi-
center study in Latin America (LA) – the PLATINO study –
highlighted the high prevalence of COPD in this region [2].
The literature shows that COPD and poor lung function are
important predictors for all-cause, cardiovascular and respiratory
mortality[3–7], but there is controversy regarding which lung
function parameter is the best predictor.
Most of the evidence comes from high-income countries [3–8].
Results from one of the few studies outside this more affluent
population showed that forced expiratory volume in one second
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(FEV1) was an important predictor of overall and cancer mortality,
but forced vital capacity (FVC) was not measured [9].
A recent publication presenting spirometric data from 17
countries concluded that lung function differs substantially
between regions worldwide, and that such differences are not
explained by variation in the distribution of height, age, gender,
weight, residence, or educational level [10]. Compared with North
America or Europe, FEV1 and FVC adjusted for height and
gender were lower in several regions including South America
[10]. In this study, there was no attempt to correlate lung function
with mortality.
The present analyses are aimed at evaluating how reliable are
COPD (according to different spirometric criteria) and lung
function as predictors of overall and cause-specific mortality in
three urban sites in LA, by following up a population based
cohorts which were part of the PLATINO study.
Methods
The detailed methods of the PLATINO baseline [11] and
follow-up [12] are available elsewhere. Between 2003 and 2005,
population-based surveys were conducted in five LA metropolitan
areas: Sao Paulo (Brazil), Mexico City (Mexico), Montevideo
(Uruguay), Santiago (Chile) and Caracas (Venezuela). We
interviewed 1000 subjects aged 40 years or older in Sao Paulo,
1063 in Mexico City, 943 in Montevideo, 1208 in Santiago and
1357 in Caracas [2].
Information collected at baseline by means of a standardized
questionnaire is available at: http://www.platino-alat.org.
Spirometry was undertaken in 99.0% of the sample using a
portable, battery-operated, Easy One spirometer (ndd Medical
Technologies, Switzerland); tests were performed at baseline and
15 minutes after 200 mg of salbutamol according to the American
Thoracic Society (ATS) criteria of acceptability and reproducibil-
ity [13]. The quality control showed that over 90% of the tests
fulfilled ATS criteria of quality [11].
Follow-up studies were conducted in Montevideo, Santiago and
Sao Paulo 5, 6 and 9 years after the baseline surveys, respectively.
Only individuals with valid spirometric data at baseline were
eligible for follow-up.
The outcomes were all-cause mortality and mortality due to
cardiovascular diseases, respiratory diseases and cancer. Lung
cancer was considered among cancer deaths and not among the
respiratory causes of mortality. Deaths were identified through the
household interviews; for subjects known to have died, death
certificates were obtained from the National Death Registry from
each country. Quality of death certificates was evaluated by an
expert (R.L.) who identified also the underlying cause of death.
The percentage of ill-defined causes in the death certificates from
Montevideo was higher than in the other sites (49.3% against
14.7% in Santiago and 11.1% in Sa˜o Paulo). We opted to present
the analyses on overall rates and those on causes of deaths for the
three sites, and, as supplementary material the data without
Montevideo (Table S9 in File S4).
Data analyses contained the description of the sample and the
mortality incidence rates for site and by gender, and the crude and
age-adjusted mortality rates using the WHO reference population
[14]. The Kaplan-Meier method was used to derive survival
curves.
Adjustment for age and country and for additional confounders
was carried out using Cox regression, and hazard ratios (HR) were
calculated for the following exposures: presence of COPD and
lung function parameters. COPD was defined using several
criteria: a) FEV1/FVC ,lower limit of normal (LLN) [15] – the
lower 5th percentile for predicted post-bronchodilator (BD) FEV1/
FVC based on PLATINO equations [16]; b) a ratio of the post-BD
FEV1 over FVC below 0.70 (GOLD 1-4); c) the previous criteria
plus a FEV1 below 80% predicted (GOLD 2-4) [1]; and d)
FEV1/FVC6 ,LLN – the lower 5
th percentile for predicted post-
BD FEV1/FVC6 based on PLATINO equations [16]. The lung
function parameters analyzed were: post-BD FEV1 (Liters) and
FVC (Liters).
The main confounders were: gender, age (40–49, 50–59 and $
60 years of age) and age as a quadratic term, schooling (0–4 and $
5 years), current status of smoking (never, former and current) and
pack-years (average number of cigarettes packs/day times the
number of years smoked). A comorbidity score was calculated by
counting the number of self-reported doctor diagnosed diseases
(we added one point for each comorbidity): heart disease,
hypertension, stroke, diabetes, lung cancer, ulcer and tuberculosis.
Health status was assessed using the physical domain from the
Short-Form-12 questionnaire (continuous variable) [17]. Weight
and height were measured and body mass index (BMI) was
calculated as the ratio weight (kg)/height (m)2 (kg/m2) (categorized
into two groups: normal/underweight and overweight/obesity).
All the analyses took into account the sampling scheme with
adjustment for ‘‘country’’ and were stratified by gender.
Sensitivity, specificity, positive (PPV) and negative predictive
values (NPV) were calculated for overall and all-causes mortality
for all sites, according to the different criteria for COPD.
Additionally, receiver operating characteristics (ROC) curves
stratified by gender were used to quantify whether FEV1 or FVC
was the best predictor for all-cause mortality and specific causes
mortality. The Youden’s index (sensitivity + specificity – 1) was
used as a measure of overall diagnostic effectiveness representing
the maximum vertical distance between the ROC curve and the
diagonal line [18]. This index was used to define the optimal cut-
off point for both lung function parameters. To standardize
mortality analyses across sites, we took the shortest duration of
follow up (5.3 years in Montevideo) and used the same period in
the other two sites.
Ethical approval was obtained by local Institutional Review
Boards at baseline and at follow-up.
Results
There were 885 eligible individuals for follow-up in Montevi-
deo, 1173 in Santiago and 963 in Sao Paulo. Information was
obtained for 85.6%, 84.7% and 77.7%, respectively. These
included 71 deaths in Montevideo, 95 in Santiago and 135 in
Sao Paulo. Death certificates were successfully obtained for 76.1%
of the deaths in Montevideo, 88.3% in Santiago and 91.8% in Sao
Paulo [12].
Table 1 describes the baseline characteristics of the sample from
the three sites combined and the number of deaths within the
follow-up period. Women were older and had less schooling than
men; around 3/4 of men and half of the women were smokers.
Deaths were more frequent among subjects who were older, had
less schooling and among those with normal BMI more noticeable
for men than for women. Among those who died, both genders,
the mean comorbidity score was higher, while lung function
parameters and health status were lower. Follow up rates for each
category of independent variables were around 80% (Table 1).
More detailed information is available elsewhere [12].
Figure 1 presents crude survival curves using the Kaplan Meier
method. Among men, survival rates appeared to be lower in Sao
Paulo as compared to the other cities from year 2 onwards, but this
difference was not statistically significant (log rank test p = 0.11).
Mortality and Lung Function in the PLATINO Study
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Among women, the survival curves were similar in all sites (log
rank test p = 0.21).
Table 2 displays the crude and age-standardized mortality rates
(SMR) by country and gender. In agreement with the survival
curves, SMR were similar in Montevideo and Santiago, but
appeared to be slightly higher in Sao Paulo. Most SMR tended to
be lower in women than in men. Cardiovascular deaths were the
leading causes of death for both genders in Santiago and Sao
Paulo, and for men in Montevideo. Cancer and respiratory deaths
were the next two most common causes of death overall.
Table 3 presents the age and site-adjusted hazard ratio (HR) for
mortality and after additional adjustment for other confounders
according to the presence of COPD (defined by different
spirometric criteria) and lung function in the baseline. With the
exception of cancer deaths, all HR for men were greater than one,
but results for women were less consistent. HRs adjusted for
confounders for which the 95% CI did not include unity are
described below. For the whole sample, being diagnosed with
COPD as defined by the FEV1/FVC,LLN criterion at baseline
was associated with a 43% increase in overall mortality; the
corresponding increases were 101% for GOLD 2-4, 46% for
Table 1. Baseline characteristics for all sites (Montevideo, Santiago and Sao Paulo), number of deaths and follow up rates (The
PLATINO Study).
Males Females
Eligible subjects Deaths Eligible subjects Deaths
Follow up rates (all
sample)
Variables N (%) N (rate/1,000) N (%) N (rate/1,000) %
Age
40–49 432 (34N8) 15 (34) 585 (32N9) 12 (20) 79N2
50–59 392 (31N6) 30 (75) 530 (29N8) 29 (54) 82N3
60+ 418 (33N6) 101 (232) 664 (37N3) 114 (163) 83N5
Schooling
5+ 895 (72N1) 76 (83) 1221 (68N9) 63 (50) 81N9
0–4 347 (27N9) 70 (194) 551 (31N1) 92 (158) 81N1
Current smoker
No 299 (24N1) 31 (100) 867 (48N7) 77 (85) 81N4
Yes 941 (75N9) 115 (119) 912 (51N3) 78 (84) 81N8
BMI
Normal/Underweight 401 (32N3) 67 (161) 512 (28N9) 48 (90) 80N0
Overweight 839 (67N7) 79 (92) 1263 (71N1) 107 (82) 82N4
COPD
GOLD 1-4 281 (22N6) 62 (221) 243 (13N7) 44 (181) 83N2
FEV1/FVC ,LLN 217 (17N8) 44 (203) 164 (9N5) 19 (116) 81N6
GOLD 2-4 102 (8N2) 33 (324) 99 (5N6) 19 (192) 85N1
FEV1/FVC6 ,LLN 136 (11N2) 32 (235) 115 (6N7) 16 (139) 82N5
Pack years [mean (SD)] 17N62 (22N83) 28N5 (33N1) 7N29 (13N51) 8N62 (18N78) 12N2 (19N8)
Comorbidities score [mean (SD)] 0N79 (0N86) 1N25 (1N15) 1N09 (0N98) 1N46 (1N15) 1N03 (0N98)
SF-12 physical domain [mean (SD)] 52N66 (6N85) 49N18 (9N67) 49N21 (9N39) 44N86 (11N16) 50N0 (8N98)
Lung function (post-BD)
FEV1 (liters) [mean (SD)] 3N28 (0N71) 2N63 (0N85) 2N33 (0N55) 1N80 (5N6) 2N66 (0N80)
FVC (liters) [mean (SD)] 4N30 (0N82) 3N81 (0N89) 2N96 (0N62) 2N41 (6N7) 3N47 (0N98)
Note: data for continuous variables (pack-year smoking, comorbidities score, SF-12 and lung function parameters) are presented as mean (standard deviation (SD) in
survival individuals (eligible subjects column) and mean (SD) in those who died (deaths column).
FEV1 – forced expiratory volume in one second; FVC – forced vital capacity; FVC6 - forced vital capacity in 6 seconds; BD – bronchodilator.
doi:10.1371/journal.pone.0109732.t001
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GOLD 1-4 and 50% according to FEV1/FEV6 ,LLN. For
cardiovascular mortality, significant associations were found with
the GOLD 2-4 (168% increase) and with GOLD 1-4 (78%). All
these associations were significant for men but not among women.
Patterns for cardiovascular deaths were similar to those of
overall mortality, although some of the associations for both
genders and for men were no longer significant, possibly due to
small numbers. None of the associations for women were
significant. Due to the small number of respiratory deaths,
patterns are not as clear, but most HR were increased. There
were no significant associations between COPD under any
definition with cancer deaths. We performed a supplementary
analysis for the outcomes ‘‘respiratory mortality including lung
cancer’’ and ‘‘for lung cancer as a single outcome category’’
according to different spirometric criteria of COPD only for lung
cancer mortality (Table S1 in File S1). Most HR are increased in
the analysis of the outcome ‘‘mortality for lung cancer’’, although
the results did not reach a statistical significance.
Table 4 shows the predictive ability of the COPD diagnostic
criteria, as currently defined (for all-cause mortality). Results are
shown for all sites combined. The GOLD 1-4 criteria show the
highest sensitivity (40%) for mortality whereas the other three
criteria ranged from 20% to 27%. In terms of specificity, the
highest was achieved by GOLD 2-4 (95%) followed by FEV1/
FEV6 (92%) whereas the other criteria had values for specificity
that were below 90%. PPV were below 25% for all criteria, and
NPV were all above 90%. Tables S2, S3 and S4 in File S2 show
the cause of death and gender stratified results, which are well in
line with the all-cause results described above.
Out of the spirometric measures in the adjusted analysis, an
increase of 1 Liter in the FEV1 showed a HR of 0.62 (95%CI 0.46;
0.83) for overall mortality, 0.38 (95%CI 0.23; 0.61) for cardiovas-
cular mortality and 0.26 (95%CI 0.08; 0.80) for respiratory
mortality in both genders combined. FVC did not show a
significant association with overall mortality (HR=0.81, 95%CI
0.61; 1.07) for both genders combined, although it was associated
with lower cardiovascular mortality (HR=0.51, 95%CI 0.33;
0.78) (data not shown).
Figure 2 shows the ROC curves for FEV1 and FVC stratified by
gender according to all-cause, cardiovascular and respiratory
mortality. Due to the small number of respiratory deaths within
the 5.3 years period among women, ROC curves were not
calculated. In all other comparisons, the area under the curve for
FEV1 was greater than for FVC, even though some of the
differences were not statistically significant. The p values for all-
cause mortality in men and women were ,0.001 and 0.04,
respectively, and for cardiovascular mortality these were 0.002 and
0.07, respectively. The p value for comparing the two curves for
respiratory mortality in men was 0.49.
We used the Youden’s index to estimate the cut off points
associated with the optimal combination of specificity and
sensitivity for the two spirometric measures. These are displayed
as dots in Figure 2 (full results available in Tables S5, S6, S7 and
S8 in File S3). The cutoffs varied according to the outcomes; for
FEV1 the cut-off point ranged from 1.9 L for respiratory mortality
to 2.8 L for overall mortality, while the FVC cut-off ranged from
3.2 for all causes mortality to 4.0 for cardiovascular mortality.
Similar variations were observed among women.
Figure 1. Survival curves according to the Kaplan-Meier method by site and gender. The PLATINO Study.
doi:10.1371/journal.pone.0109732.g001
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Discussion
These prospective analyses describe mortality rates according to
COPD status and lung function measured at baseline in
population-based samples of adults living in three LA metropolises,
with follow up periods ranging from five to nine years.
Standardized methods were used to classify subjects at baseline,
and follow up rates were above 75%.
Our findings on mortality rates were consistent with the
literature. Deaths were more common among men than women,
and persons from Sao Paulo had higher rates than those from
Santiago and Montevideo. According to the Global Burden of
Disease Study 2010 [19], life expectancy in Brazilian males is 70.5
years compared to 77.7 years for females, and the corresponding
figures for Uruguay are 72.6 y and 80.4 y, and for Chile 75.5 y vs.
81.5 y [19]. Cardiovascular, respiratory and cancer were the main
causes of death, in accordance with the literature from LA [19,20].
Poor lung function is an important predictor of overall,
cardiovascular and respiratory mortality [3,5–8], but there is
controversy regarding which parameter shows the greatest
predictive ability [3,4,21–25]. Most of the evidence is derived
from cohorts studies in high-income settings, such as the
Atherosclerosis Risk in Communities (ARIC), the Copenhagen
City Heart, the Cardiovascular Health and the NHANES
(National Health and Nutrition Examination Survey) studies
[3,6,23,24,26]. In addition, none of these studies used broncho-
dilators prior to spirometric evaluation, and this may lead to
misclassification of COPD status [27]. An earlier publication of the
PLATINO baseline survey showed that the prevalence of airflow
obstruction measured by the GOLD 1-4 criteria was 35% higher
before bronchodilator use, compared to prevalence after its use
[15].
In the analyses adjusted by site and age, the four spirometric
tested diagnostic criteria for COPD predicted all-cause, cardio-
vascular and respiratory mortality for both genders combined and
for men. For women, results were less consistent in terms of
statistical significance, but COPD tended to be associated with
increased risk. After adjustment for several confounders, the HR
tended to be attenuated, but in general COPD was associated with
greater risk of overall and cardiovascular mortality. Including lung
cancer among the respiratory causes of mortality the results were
quite similar.
The lack of significance in the associations with respiratory
causes must be interpreted in light of the small number of deaths in
this category and as a result of the low statistical power. There
were no associations between COPD status and cancer mortality;
however, in the supplementary analysis with ‘‘lung cancer
mortality’’ as a single outcome according to the different
spirometric criteria of COPD, we were able to detect an increase
in all HR although the results did not reach statistical significance
due to the small sample size (only 10 deaths by lung cancer out of
46 cancer deaths).
These findings from the survival analyses are reflected by the
calculations of specificity and sensitivity. The latter tended to be
very low for all four diagnostic criteria, being a little better for
GOLD 1-4 (40% for overall mortality). Specificity on the other
hand tended to be high for the four criteria, particularly GOLD 2-
4. Consistently, PPV were low, and NPV were high. None of the
four diagnostic criteria of COPD was sufficiently sensitive to be
recommended as a predictor of mortality rates.
Regarding the lung function parameters, FEV1 was clearly a
better predictor of mortality than FVC; even after adjusting for
potential confounders for mortality, low FEV1 remained as a
significant predictor for overall mortality in both genders and for
cardiovascular mortality in men. These results were confirmed by
the ROC curves showing that the area under the curve for FEV1
was significantly greater than that for FVC, again for all-cause
mortality in both genders and for cardiovascular mortality in men.
The lack of significant associations with respiratory mortality is
likely due to the small number of deaths, particularly among
women. We attempted to suggest cut-off points for FEV1 or FVC
Table 4. Validity parameters for prediction of overall mortality for all sites according to different criteria of Chronic Obstructive
Pulmonary Disease (COPD) (The PLATINO Study).
Diagnostic classification
Sensitivity %
(95%CI)
Specificity %
(95%CI)
Positive predictive
value % (95%CI)
Negative predictive
value % (95%CI) Youden’s index
Both Genders
LLN 26N7 (21N0; 33N0) 88N2 (86N9; 89N4) 15N5 (12N0; 19N5) 93N7 (92N7; 94N6) 14N9
GOLD 2-4 20N7 (15N7; 26N4) 94N5 (93N6; 95N4) 24N4 (18N6; 30N9) 93N3 (92N3; 94N2) 15N2
GOLD 1-4 40N1 (33N8; 46N6) 84N6 (83N2; 85N9) 18N1 (14N9; 21N7) 94N3 (93N3; 95N2) 24N7
FEV1/FEV6 20N4 (15N3; 26N3) 92N4 (91N4; 93N4) 17N9 (13N4; 23N2) 93N5 (92N5; 94N4) 12N8
Males
LLN 36N9 (28N0; 46N6) 84N1 (81N8; 86N2) 18N9 (13N9; 24N7) 93N0 (91N2; 94N5) 21N0
GOLD 2-4 26N1 (18N4; 34N9) 93N7 (92N1; 95N0) 30N4 (21N7; 40N3) 92N3 (90N6; 93N8) 19N8
GOLD 1-4 47N1 (37N8; 56N4) 80N0 (77N5; 82N3) 19N9 (15N4; 25N1) 93N4 (91N7; 94N9) 27N1
FEV1/FEV6 27N0 (19N0; 36N3) 90N4 (88N5; 92N1) 22N1 (15N4; 30N0) 92N5 (90N8; 94N0) 17N4
Females
LLN 16N4 (10N0; 24N6) 91N0 (89N4; 92N3) 11N0 (6N6; 16N8) 94N1 (92N8; 95N2) 7N4
GOLD 2-4 15N3 (9N3; 23N0) 95N1 (94N0; 96N1) 18N2 (11N1; 27N2) 94N0 (92N8; 95N1) 10N4
GOLD 1-4 33N1 (24N7; 42N3) 87N7 (86N0; 89N3) 16N0 (11N7; 21N3) 94N9 (93N6; 95N9) 20N8
FEV1/FEV6 13N6 (7N8; 21N5) 93N8 (92N5; 94N9) 13N0 (7N5; 20N6) 94N1 (92N8; 95N2) 7N4
Youden’s index: sensitivity + specificity – 1.
doi:10.1371/journal.pone.0109732.t004
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for predicting mortality, but this was not possible given that the
ROC curves vary by gender and mortality cause.
The link between poor lung function and COPD as predictors
of all-cause and cardiovascular mortality is supported by studies
suggesting an interplay of systemic inflammation with airflow
obstruction in the development of cardiac disease [3,6]. Sin and
Man [28] evaluating the potential role of systemic inflammation in
COPD subjects showed the presence of systemic inflammation
even in moderate COPD.
Some limitations of the present study should be mentioned.
Quality of death certificates is very heterogeneous globally,
particularly in low and middle-income countries [29]. In the
Figure 2. Receiver operator characteristic (ROC) curves for mortality according to the forced expiratory volume in the first second
(FEV1) and forced vital capacity (FVC), stratified by gender. The PLATINO Study.
doi:10.1371/journal.pone.0109732.g002
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three sites, deaths were ascertained directly by interviewing family
members, but causes of death relied on death certificates. This was
particularly problematic in Montevideo where death certificates
were manually searched, which probably explains the lower
percentage of those which were located (76.1%) compared to
Santiago and Sao Paulo (88.3% and 91.8%, respectively). Another
limitation was the poor quality of the information on causes of
death in Montevideo with nearly 50% of certificates reporting ill-
defined causes. Due to this limitation, we performed two sets of
cause-specific analyses for hazard ratios, one including the three
sites and another excluding Montevideo. Both sets of results were
very similar (results shown as table S8 in File S3).
The fact that we have only two points in time for lung function
parameters poses some statistical limitation for measuring the
association of lung function decline and mortality; we hope to have
a third follow-up visit in the PLATINO study and then we will be
able of carrying out more robust analysis for lung function decline
and its association with mortality.
Someone could also argue that categorizing subjects into racial/
ethnical groups is not always a good proxy for genetic background.
Some authors found a good correlation between self-defined race
with inferred genetic clusters [30,31], but the opposite has also
been found [32] and the possible lung function misestimating
using predictive equations based on self-reported race alone [33].
We did not perform the genomic ancestry analysis of our
population as in most of the studies, but data not yet published
from Brazil showed that self-report skin color has a good
correlation with genomic ancestrality.
In spite of these limitations, this study has several strengths. It is
the first prospective population-based study aimed at evaluating
COPD (defined by different spirometric criteria) and pulmonary
function as predictors of mortality in LA. The high follow up rates
and the quality of the post-bronchodilator spirometry data
reinforce the present findings. The consistency of the results
between the several sets of analyses presented above is also
reassuring.
COPD increases the risk of mortality in middle income
countries consistent with previous studies mainly from developed
countries. Our results show that FEV1 predicts mortality better
than FVC in a population based cohort contributing to still an
area of debate in the literature. Some of the findings in the
literature come from specific groups of subjects and cannot be
extrapolated to the general population; we believe that population
based studies are the most reliable sources for drawing conclusions
on the best lung function parameter to predict mortality. Burney
found that survival was strongly associated with FVC adjusted for
FEV1, but not the other way round in asymptomatic subjects from
the ARIC study [26]; this group nevertheless had a substantial
number of people with airway obstruction according to the author;
interestingly, FEV1 was a better predictor for survival when
analysis was carried out among the symptomatic group. The
conclusion of the analysis cannot be applied to the general
population because the studied sample was not representative of
the general population. Another paper [34] showed that addition
of FVC with the Framingham Risk Score offered significant
incremental prediction of mortality in the intermediate risk group;
the author also mentions that FEV1 relationships with mortality
were weaker (data not shown in the paper); again, the analyzed
sample was comprised of never-smokers subjects and without
COPD diagnosis, therefore it is not a population based sample.
The importance of COPD and lung function as risk factors for
mortality reinforces the need for strengthening preventive efforts,
in particular tobacco control measures given the importance of
smoking as identified in the original PLATINO findings [2] as well
as in the ample global literature.
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